Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Ayyoub

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Plos One|July 13, 2011
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapyAhmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, et al.
Annales Pharmaceutiques Francaises|October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer careFlorence Ranchon, Florian Slimano, Maha Ayyoub, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2006
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsElke Jäger, Julia Karbach, Sacha Gnjatic, et al.
Science Immunology|June 8, 2023
Distant antimetastatic effect of enterotropic colon cancer-derived α4β7Virginie Feliu, Carlos Gomez-Roca, Marie Michelas, et al.
Cancer Immunity|October 10, 2003
SSX antigens as tumor vaccine targets in human sarcomaMaha Ayyoub, Michelle Brehm, Geneviève Metthez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical TrialAnne Montfort, Thomas Filleron, Mathieu Virazels, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Journal for Immunotherapy of Cancer|July 15, 2024
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective - a SENTICOL ancillary studyGaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, et al.
Cancer Immunity|June 28, 2008
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancerPedro M S Alves, Nicole Lévy, Brian J Stevenson, et al.
Cancers|August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis BlockadeCarlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Plos One|July 13, 2011
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapyAhmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, et al.
Annales Pharmaceutiques Francaises|October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer careFlorence Ranchon, Florian Slimano, Maha Ayyoub, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2006
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsElke Jäger, Julia Karbach, Sacha Gnjatic, et al.
Science Immunology|June 8, 2023
Distant antimetastatic effect of enterotropic colon cancer-derived α4β7Virginie Feliu, Carlos Gomez-Roca, Marie Michelas, et al.
Cancer Immunity|October 10, 2003
SSX antigens as tumor vaccine targets in human sarcomaMaha Ayyoub, Michelle Brehm, Geneviève Metthez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical TrialAnne Montfort, Thomas Filleron, Mathieu Virazels, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Journal for Immunotherapy of Cancer|July 15, 2024
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective - a SENTICOL ancillary studyGaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, et al.
Cancer Immunity|June 28, 2008
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancerPedro M S Alves, Nicole Lévy, Brian J Stevenson, et al.
Cancers|August 12, 2022
Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis BlockadeCarlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, et al.
Pageof 9